Timpani Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Timpani Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-43,958	Closed	-$797K	–	121
2016 Q3	$797K	Buy	+43,958	New	+$859K	0.32%	83
2015 Q4	–	Sell	-137,521	Closed	-$2.73M	–	111
2015 Q3	$2.73M	Sell	137,521 -176,798	-56%	-$5.59M	1.1%	36
2015 Q2	$10.9M	Sell	314,319 -57,125	-15%	-$1.74M	3.16%	2
2015 Q1	$9.65M	Buy	371,444 +125,530	+51%	+$2.3M	2.88%	3
2014 Q4	$3.17M	Buy	245,914 +96,198	+64%	+$1.2M	1.25%	34
2014 Q3	$1.84M	Sell	149,716 -52,907	-26%	-$615K	0.84%	52
2014 Q2	$3.21M	Sell	202,623 -47,798	-19%	-$682K	1.44%	25
2014 Q1	$3.79M	Buy	250,421 +85,157	+52%	+$962K	2%	15
2013 Q4	$1.26M	Buy	+165,264	New	+$891K	0.63%	60

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Timpani Capital Management's HZNP Position: Q4 2016 in Review

Timpani Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2016, closing a stake of 43,958 shares — an estimated $797K sold.

Timpani Capital Management first reported a position in HZNP in Q4 2013 and held it in 9 quarters. The position peaked at $10.9M in Q2 2015. 234 funds tracked by Wall St. Rank hold HZNP as of Q4 2016.

Timpani Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2016 after selling out during the quarter.
Timpani Capital Management sold 43,958 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2016, an estimated $797K.
Timpani Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2013 and held it in 9 quarters.
Timpani Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $10.9M in Q2 2015.
234 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2016.

Based on Timpani Capital Management's 13F filing for Q4 2016, filed 9 Feb 2017.